Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer
Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Cipatinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This
study is designed to evaluate the safety and tolerability of cipatinib in patients with HER2
positive or uncertain advanced breast cancer:
1. To evaluate the safety and tolerability of cipatinib, and the maximum tolerated dose
(MTD) and dose-limiting toxicity (DLT)
2. To determine the pharmacokinetic profile of cipatinib and its metabolites
3. To assess preliminary antitumor activity
4. To determine preliminary regimen for phase II study
5. To determine the relation of expression of HER-1 and HER-2 to the antitumor activity.